Zimelidine: a review of its pharmacological properties and therapeutic efficacy in depressive illness.

Abstract:

:Zimelidine is a new antidepressant, which is structurally unrelated to the tricyclic and tetracyclic antidepressants. The pharmacological profile of zimelidine is different to that of other antidepressants in that it appears to owe the major part of its activity to the inhibition of serotonin uptake within the central nervous system. It appears that the demethylated metabolite, norzimelidine, may be responsible for most of the pharmacological activity. Studies to date suggest that zimelidine has overall efficacy comparable with that of amitriptyline, desipramine, maprotiline and doxepin in depressive illness, but at dosages which have achieved a similar overall clinical improvement zimelidine does not cause sedation, and anticholinergic side effects are mild and occur infrequently. Preliminary evidence suggests that zimelidine is effective against concomitant anxiety in depressed patients, and that it may also be useful in treating phobic anxiety. Zimelidine appears less likely to cause serious cardiotoxicity, in therapeutic dosages or an overdosage, than the tricyclic antidepressants, but it has not been studied in patients with cardiovascular disease. Sleep disturbance has occurred significantly more frequently during zimelidine therapy than during therapy with other sedative antidepressants, but whether this simply reflects the absence of sedation with zimelidine, or an effect on sleep as such, is presently unclear. Zimelidine appears to be effective and well tolerated in elderly patients. Thus, some aspects of the drug's profile (e.g. apparent low incidence of anticholinergic effects or drowsiness) may offer potential advantages in some patients; however, clinical experience with zimelidine to date has been limited, and further well designed studies are required to define the role of the drug more clearly in treating depressive illness compared with other antidepressants, and particularly to define whether some types of depression may respond more readily to zimelidine than to other antidepressants.

journal_name

Drugs

journal_title

Drugs

authors

Heel RC,Morley PA,Brogden RN,Carmine AA,Speight TM,Avery GS

doi

10.2165/00003495-198224030-00001

subject

Has Abstract

pub_date

1982-09-01 00:00:00

pages

169-206

issue

3

eissn

0012-6667

issn

1179-1950

journal_volume

24

pub_type

杂志文章,评审

相关文献

DRUGS文献大全
  • Peficitinib: First Global Approval.

    abstract::Peficitinib [Smyraf® (Astellas Pharma)] is a Janus kinase (JAK)1, JAK2, JAK3 and tyrosine kinase (Tyk)2 (pan-JAK) inhibitor recently approved in Japan for the treatment of rheumatoid arthritis. Inhibition of JAK suppresses the activation of cytokine signalling pathways involved in inflammation and joint destruction in...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01131-y

    authors: Markham A,Keam SJ

    更新日期:2019-06-01 00:00:00

  • Corticosteroids and adrenal suppression. Characterising and avoiding the problem.

    abstract::Glucocorticoids are used for a variety of illnesses. One of their major complications is suppression of the hypothalamic-pituitary-adrenal axis, rendering a patient unable to respond to stress. The risk of this suppression may be minimised by the use of short-acting glucocorticoid preparations, administration of the e...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198938050-00008

    authors: Helfer EL,Rose LI

    更新日期:1989-11-01 00:00:00

  • Coronary thrombolysis for evolving myocardial infarction.

    abstract::An acute thrombus at the site of an atherosclerotic obstruction is the usual cause of myocardial infarction. Thrombolytic therapy is an exciting new therapy for reducing the extent of myocardial infarction by lysing intracoronary clots. Such therapy has now been widely applied by: prolonged intravenous infusion of str...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198428050-00004

    authors: Spann JF,Sherry S

    更新日期:1984-11-01 00:00:00

  • Tipranavir: a review of its use in the management of HIV infection.

    abstract::Tipranavir (Aptivus) is a selective nonpeptidic HIV-1 protease inhibitor (PI) that is used in the treatment of treatment-experienced adults with HIV-1 infection. Tipranavir is administered orally twice daily and must be given in combination with low-dose ritonavir, which is used to boost its bioavailability. The durab...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200868100-00006

    authors: Orman JS,Perry CM

    更新日期:2008-01-01 00:00:00

  • Remifentanil: a review of its use during the induction and maintenance of general anaesthesia.

    abstract::Remifentanil (Ultiva), a fentanyl derivative, is an ultra-short acting, nonspecific esterase-metabolised, selective mu-opioid receptor agonist, with a pharmacodynamic profile typical of opioid analgesic agents. Notably, the esterase linkage in remifentanil results in a unique and favourable pharmacokinetic profile for...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200565130-00007

    authors: Scott LJ,Perry CM

    更新日期:2005-01-01 00:00:00

  • Drug treatment of stroke. Current status and future prospects.

    abstract::Despite advances in the understanding of the mechanism of cerebral injury during focal ischaemia, the best treatment of cerebral ischaemia is still prevention. The pathophysiological mechanisms that contribute to cerebral ischaemia are discussed relative to the many therapeutic interventions that have been attempted. ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198835040-00005

    authors: Sila CA,Furlan AJ

    更新日期:1988-04-01 00:00:00

  • Current and potential pharmacological treatment options for maintenance therapy in opioid-dependent individuals.

    abstract::Opioid dependence, manifesting as addiction to heroin and pharmaceutical opioids is increasing. Internationally, there are an estimated 15.6 million illicit opioid users. The global economic burden of opioid dependence is profound both in terms of HIV and hepatitis C virus transmission, direct healthcare costs, and in...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11597520-000000000-00000

    authors: Tetrault JM,Fiellin DA

    更新日期:2012-01-22 00:00:00

  • Aggravation of ventricular arrhythmia. A drug-induced complication.

    abstract::Each antiarrhythmic agent can cause side effects, but most of these are easily recognised by the patient or physician. However, one potentially serious side effect common to all of these drugs is aggravation of ventricular arrhythmia. Often this is without symptoms and goes unrecognised by the patient. It occurs in 11...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198500294-00009

    authors: Podrid PJ

    更新日期:1985-01-01 00:00:00

  • Antiviral therapy in human immunodeficiency virus infections. Current status (Part I).

    abstract::Antiviral therapy has in the past met with limited success and only a few antiviral drugs have been available. The human immunodeficiency virus (HIV) epidemic has created an urgent need for the development of antiviral therapy against this infection. HIV replication offers several targets for inhibitory compounds, the...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199345040-00002

    authors: Sandström E,Oberg B

    更新日期:1993-04-01 00:00:00

  • Correction to: Pexidartinib: First Approval.

    abstract::The original article has been corrected. ...

    journal_title:Drugs

    pub_type: 杂志文章,已发布勘误

    doi:10.1007/s40265-020-01280-5

    authors: Lamb YN

    更新日期:2020-03-01 00:00:00

  • Valsartan/hydrochlorothiazide: a review of its use in the management of hypertension.

    abstract::Valsartan/hydrochlorothiazide is a fixed-dose (valsartan 80, 160 or 320mg plus hydrochlorothiazide 12.5 or 25mg) angiotensin II receptor blocker/diuretic drug combination indicated for the treatment of patients with essential hypertension not adequately controlled by monotherapy.There is ample evidence that valsartan/...

    journal_title:Drugs

    pub_type: 杂志文章,meta分析,评审

    doi:10.2165/00003495-200666140-00011

    authors: Wagstaff AJ

    更新日期:2006-01-01 00:00:00

  • Impact of nifedipine on vascular smooth muscle cell differentiation. Implications for atherogenesis.

    abstract::Although vascular smooth muscle cells (SMCs) play a key role in the development of atherosclerotic lesions, they are not a homogeneous cell type. Myosin has been used as a marker of SMC differentiation in order to identify distinct SMC populations in the adult rabbit aorta. The medial layer of the normal adult aorta c...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199400481-00003

    authors: Pauletto P,Da Ros S,Zoleo M

    更新日期:1994-01-01 00:00:00

  • Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.

    abstract:UNLABELLED:Oxaliplatin is a platinum compound that inhibits DNA synthesis, primarily by causing intrastrand cross-links in DNA. Oxaliplatin has a broad spectrum of antineoplastic activity and has demonstrated a lack of cross-resistance with other platinum compounds. In patients with metastatic colorectal cancer, intrav...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200060040-00005

    authors: Culy CR,Clemett D,Wiseman LR

    更新日期:2000-10-01 00:00:00

  • Avapritinib: First Approval.

    abstract::Avapritinib (AYVAKIT™) is a potent and selective tyrosine kinase inhibitor of platelet-derived growth factor receptor alpha (PDGFRA) and KIT activation loop mutants. It is being developed by Blueprint Medicines for the treatment of gastrointestinal stromal tumours (GIST), solid tumours and systemic mastocytosis. Avapr...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01275-2

    authors: Dhillon S

    更新日期:2020-03-01 00:00:00

  • Cenegermin: A Review in Neurotrophic Keratitis.

    abstract::Cenegermin (Oxervate™), an ophthalmic solution containing 20 µg/mL of recombinant human nerve growth factor (rhNGF), is the first drug to be approved for the treatment of neurotrophic keratitis (NK; also referred to as neurotrophic keratopathy). In the registration trials, the majority of adults with moderate or sever...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01289-w

    authors: Deeks ED,Lamb YN

    更新日期:2020-04-01 00:00:00

  • Comparison of nimesulide and diclofenac in the prevention and treatment of painful inflammatory postoperative complications of general surgery.

    abstract::In a double-blind study, 40 patients scheduled for saphenectomy or inguinal hernioplasty were randomly assigned to treatment with nimesulide (200mg 3 times daily) or diclofenac (100mg 3 times daily) administered rectally. Therapy with either drug resulted in significantly less pain, oedema and hyperaemia, and resoluti...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-199300461-00038

    authors: Ramella G,Costagli V,Vetere M,Capra C,Casella G,Sogni A,Scaricabarozzi I

    更新日期:1993-01-01 00:00:00

  • Comparative efficacy, safety and pharmacokinetics of verapamil SR vs verapamil IR in hypertensive patients.

    abstract::The antihypertensive effects of the regular immediate release formulation of verapamil (verapamil IR) and the newer sustained release formulation of verapamil (verapamil SR) were compared in Hispanic patients with untreated essential hypertension. Verapamil IR was given in 3 divided doses (80 or 160mg 3 times daily) a...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-199200441-00002

    authors: Fuenmayor NT,Faggin BM,Cubeddu LX

    更新日期:1992-01-01 00:00:00

  • Botulinum neurotoxin type A free of complexing proteins (XEOMIN) in focal dystonia.

    abstract::Botulinum neurotoxin type A (BTX-A) weakens voluntary muscle strength and is an effective therapy for focal dystonia, including cervical dystonia (CD) and benign essential blepharospasm (BEB). It is also known to relieve hemifacial spasm and focal spasticity in children and adults. In addition, BTX-A has been shown to...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200767050-00003

    authors: Jost WH,Blümel J,Grafe S

    更新日期:2007-01-01 00:00:00

  • Cenobamate: First Approval.

    abstract::Cenobamate (XCOPRI®) is an oral, small molecule neurotherapeutic azole compound that is being developed by SK Life Science Inc. and Arvelle Therapeutics for the treatment of epilepsy. Based on results of two pivotal phase 2 trials, cenobamate was recently approved in the USA for use in the treatment of partial-onset s...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01250-6

    authors: Keam SJ

    更新日期:2020-01-01 00:00:00

  • Clopidogrel.

    abstract::Clopidogrel is a thienopyridine that irreversibly inhibits platelet aggregation by selectively binding to adenylate cyclase-coupled ADP receptors on the platelet surface. In animal models, clopidogrel reduced the formation of both arterial and venous thrombi. After oral administration, clopidogrel is rapidly absorbed ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199754050-00006

    authors: Coukell AJ,Markham A

    更新日期:1997-11-01 00:00:00

  • [Evaluation of the impact of peripheral obliterative arteriopathy on quality of life].

    abstract::Peripheral arterial occlusive disease is a common condition with possible serious consequences. It is usually diagnosed at the intermittent claudication stage. There are 2 objectives of treatment: to prevent ischaemic attacks and to improve quality of life. Treatment efficacy is, however, usually evaluated only in ter...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199856003-00004

    authors: Marquis P

    更新日期:1998-01-01 00:00:00

  • Pharmacologic management of advanced cervical cancer: antiangiogenesis therapy and immunotherapeutic considerations.

    abstract::As a consequence of disparities in access to and utilization of preventative healthcare, the incidence and death rates from cervical cancer remain substantial in the face of indisputable evidence that screening saves lives. While disparities persist, there will be an urgent need for research into the treatment of adva...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0481-z

    authors: Longoria TC,Tewari KS

    更新日期:2015-11-01 00:00:00

  • Inhibitory effects of nedocromil sodium on the in vitro induced migration and leukotriene formation of human granulocytes.

    abstract::Inflammatory cells, such as neutrophils and eosinophils, are thought to actively contribute to the pathogenesis of asthma since they infiltrate into the lung tissue and may be activated locally to release bronchoconstrictor mediators. In this study we provide evidence that nedocromil sodium is capable of effectively i...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198900371-00004

    authors: Bruijnzeel PL,Warringa RA,Kok PT,Hamelink ML,Kreukniet J

    更新日期:1989-01-01 00:00:00

  • Current and Innovative Pharmacological Options to Treat Typical and Atypical Trigeminal Neuralgia.

    abstract::Trigeminal neuralgia is a representative neuropathic facial pain condition, characterised by unilateral paroxysmal pain in the distribution territory of one or more divisions of the trigeminal nerve, triggered by innocuous stimuli. A subgroup of patients with trigeminal neuralgia [TN (previously defined as atypical TN...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-018-0964-9

    authors: Di Stefano G,Truini A,Cruccu G

    更新日期:2018-09-01 00:00:00

  • Canagliflozin: first global approval.

    abstract::Canagliflozin (Invokana™), an oral selective sodium-glucose co-transporter 2 (SGLT2) inhibitor, is under global development with Mitsubishi Tanabe Pharma and Janssen Pharmaceuticals, a subsidiary of Johnson and Johnson, for the treatment of type 2 diabetes mellitus. SGLT2 are mainly located in the proximal tubule of t...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-013-0064-9

    authors: Elkinson S,Scott LJ

    更新日期:2013-06-01 00:00:00

  • Ventricular arrhythmias in patients with myocardial infarction and ischaemia. The role of serum potassium.

    abstract::An association between low serum potassium concentrations and ventricular arrhythmias has been observed by a number of investigators in patients with both acute myocardial infarction and symptomatic angina. The increased frequency of ventricular fibrillation in patients with low serum potassium concentrations has not ...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198600314-00014

    authors: Solomon RJ

    更新日期:1986-01-01 00:00:00

  • Use of oral rehydration therapy in acute watery diarrhoea. A practical guide.

    abstract::Various foods and fluids have been used in traditional treatments for diarrhoeal illnesses in infants and children for centuries. During the last 2 decades, however, with the advent of an improved scientific understanding of oral rehydration, effective treatment of dehydrating diarrhoea has been improved, expanded and...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199141040-00005

    authors: Sack DA

    更新日期:1991-04-01 00:00:00

  • Responsible prescribing of opioids for the management of chronic pain.

    abstract::The management of patients with chronic pain is a common clinical challenge. Indeed, chronic pain is often inadequately controlled in patients with cancer and in those with non-cancer chronic pain. Because of the complex nature of chronic pain, successful long-term treatment is more difficult than for acute pain. Most...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200363010-00002

    authors: Nicholson B

    更新日期:2003-01-01 00:00:00

  • Aflibercept: A Review of Its Use in Diabetic Macular Oedema.

    abstract::Aflibercept (Eylea(®)) is an anti-vascular endothelial growth factor agent indicated for intravitreal use in the treatment of diabetic macular oedema. In patients with diabetic macular oedema, significantly greater improvements from baseline to week 52 in visual acuity were seen with intravitreal aflibercept versus ma...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-015-0421-y

    authors: Keating GM

    更新日期:2015-07-01 00:00:00

  • Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease.

    abstract::Budesonide is a glucocorticoid with high topical activity, but low systemic bio-availability which results in reduced systemic effects in comparison with other glucocorticoids. To date, it has been evaluated for use in patients with inflammatory bowel disease when administered either orally as a controlled ileal relea...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199550050-00006

    authors: Spencer CM,McTavish D

    更新日期:1995-11-01 00:00:00